Savara SVRA
NASDAQ SVRA
$4.95 -0.04 (-0.90%)
As of: Nov 12, 2026 · 10:55 AM EST

Savara (SVRA) Return on Capital Employed [ROCE] (2009 - 2026)

Updated

Savara (SVRA) posted Return on Capital Employed [ROCE] of -75.88% for Q2 2026, down 3.81 percentage points from -72.07% a year earlier and down 15.47 percentage points from the prior quarter.

Analysis

Savara (SVRA) Return on Capital Employed [ROCE] (2009 - 2026) Analysis & Trends

For FY2025, Savara's Return on Capital Employed [ROCE] came in at -58.07%, down 0.90 percentage points from FY2024.

  • Annual Return on Capital Employed [ROCE] has declined for three consecutive years, with a five-year change of -12.76 percentage points (FY2020 to FY2025).
  • In prior years, Savara's Return on Capital Employed [ROCE] was -57.17% in FY2024 (-16.65 pp), -40.53% in FY2023 (-15.03 pp), -25.50% in FY2022 (+8.36 pp) and -33.86% in FY2021 (+11.46 pp).
  • Quarterly Return on Capital Employed [ROCE] has run from a low of -89.47% in Q3 2025 to a high of -24.11% in Q2 2022 over five years.
  • On a year-over-year basis, Return on Capital Employed [ROCE] has declined in each of the last 17 quarters, with an average year-over-year change of -14.89 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Capital Employed [ROCE] in the past five years was Q3 2021, with a gain of 40.61 percentage points; the weakest was Q3 2025, with a drop of 38.66 percentage points.
  • According to Business Quant data, Return on Capital Employed [ROCE] for the three prior quarters was -60.41% (Q1 2026), -69.89% (Q4 2025) and -89.47% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Savara 1.09 Bn 407.27 Mn - -99.69%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -99.69%
Jun 30, 2026 -75.88%
Mar 31, 2026 -60.41%
Dec 31, 2025 -69.89%
Sep 30, 2025 -89.47%
Jun 30, 2025 -72.07%
Mar 31, 2025 -57.69%
Dec 31, 2024 -48.88%
Sep 30, 2024 -50.81%
Jun 30, 2024 -59.07%
Mar 31, 2024 -44.50%
Dec 31, 2023 -35.46%
Sep 30, 2023 -37.50%
Jun 30, 2023 -38.53%
Mar 31, 2023 -33.09%
Dec 31, 2022 -28.16%
Sep 30, 2022 -26.24%
Jun 30, 2022 -24.11%
Mar 31, 2022 -25.22%
Dec 31, 2021 -24.80%
API Access

Savara Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=SVRA&period=max&api_key=YOUR_API_KEY